Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy. Analyst Price Forecast Suggests 12.29% Upside As of January 28, 2025, the ...

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...

Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...

Wolfe Research has recently reduced Edwards Lifesciences Corp (EW) stock to Underperform rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 16, 2024, BofA Securities ...

Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...

Please find enclosed outcome of the Board Meeting dated October 25, 2024 ...

Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...

In the fast-paced manufacturing industry, continuous improvement and process optimization are indispensable strategies for ...

Edwards Lifesciences Corp (EW) stock saw a modest uptick, ending the day at $68.99 which represents a slight increase of $0.06 or 0.09% from the prior close of $68.93. The stock opened at $68.64 and ...